J.P. Morgan’s healthcare analyst Cory Kasimov weighed in with a few insights on ZIOPHARM Oncology Inc.(NASDAQ:ZIOP), after the company released its second-quarter results and provided update on its clinical progress Monday. Kasimov rates Ziopharm shares a Neutral, without providing a price target.
Kasimov wrote, “We are updating our ZIOP model and maintaining our Neutral rating post a review of the company’s 2Q results. Not much new came from the report (there was no call). The co noted the first two CAR-T targets have been selected (though not disclosed) under it and XON’s collaboration with Merck Serono. While we acknowledge the interesting theoretical long-term potential of ZIOP’s approach to CAR-Ts, programs have yet to enter the clinic (up to 5 expected to start trials in 2015), and we await more details/proof of concept to better assess the ultimate value.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Cory Kasimov has a total average return of 7.0% and a 48.9% success rate. Kasimov is ranked #677 out of 3731 analysts.
Out of the 4 analysts polled by TipRanks, 2 rate Ziopharm Oncology Inc stock a Buy, while 2 rate the stock a Hold. With a return potential of 58.4%, the stock’s consensus target price stands at $16.67.